by Blood Advances
Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab (D-R) over lenalidomide alone (R) as post-transplant maintenance therapy for patients with newly diagnosed...
by Blood
Researchers have identified an intensive treatment to benefit individuals with newly diagnosed multiple myeloma (NDMM) who qualify for stem cell transplantation but face unfavorable outcomes due...
by Blood
Relapse after achieving complete remission (CR) is the leading cause of death following allogeneic stem cell transplantation
by ASTCT Science Highlights
The results of a Phase I/II clinical trial found that CD19-targeted chimeric antigen receptor-modified (CD19 CAR) T-cell therapy led to long-term durable responses in a subgroup of patients with...
by ASTCT Science Highlights
A proof-of-concept test of an ultrasensitive assay validated the post-allogeneic hematopoietic cell transplantation (allo-HCT) measurement of chimerism to increase measurable residual disease...
by Eleanor Mayfield, ELS
In infants with acute lymphoblastic leukemia (ALL) associated with KMT2A gene rearrangements, measurement of MRD by multicolor flow cytometry (MFC) and by PCR for fusion gene transcripts (FGT) had...